BOARD OF DIRECTORS

Kristina Burow

Kristina Burow is a partner with ARCH Venture Partners, joining the firm in 2002. Her investment focus includes biotechnology, pharmaceuticals, alternative energy and chemicals. Ms. Burow is a co-founder and director of Sapphire Energy and a director of Receptos and Limerick BioPharmaceuticals. She has participated in the funding and development of several other portfolio companies including Ensemble Discovery, Achaogen, Kythera Biopharmaceuticals, Ikaria, Accelerator Corporation and Quanterix.

Ms. Burow joined ARCH from the Novartis BioVenture Fund in San Diego, where she was involved in numerous investments in the life science sector. Previously, as an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed chemistry operations and was active in business development.

Ms. Burow holds an M.B.A. from the University of Chicago, an M.A. in chemistry from Columbia University, and a B.S. in chemistry from the University of California, Berkeley.

Mary Campbell, Observer

Mary Campbell is a managing director and founder of EDF Ventures. She has been an active investor both in healthcare and information technology companies for more than 20 years. Currently, Ms. Campbell sits on the boards of HandyLab, Health Care Solutions, Rhevision Technology, ValenTx and is a board observer for Cerenis Therapeutics, The Echo Group and QuadraSpec.

Ms. Campbell is active with The Stephen M. Ross School of Business at the University of Michigan and currently serves as an advisor to the Zell Lurie Institute for entrepreneurial studies as well as its student-run venture activity, the Wolverine Venture Fund. She is an advisor to the University of Michigan’s Life Science Institute as well as a member of the steering committee for the Michigan Strategic Economic Investment and Commercialization Board, a statewide initiative to foster research and commercialization. Ms. Campbell is also president of the Michigan Venture Capital Association, the state’s premier public policy advocate for the private equity/venture capital industry.

Ms. Campbell received an M.B.A. from the University of Michigan, an M.A. in special education from Fairfield University and a B.A. in English from the University of Michigan.

Steve Gillis, Ph.D., Observer

Dr. Steven Gillis is a managing director with ARCH Venture Partners, joining the firm in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. He is a director of Trubion Pharmaceuticals (TRBN), Allozyne, Variation Biotechnologies, Magen BioSciences, Surface Logix, PhaseRx, Accelerator and Surface Logix. He serves as director and chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST.

Dr. Gillis was a founder and director of Corixa Corp. and served as the company's chief executive officer from its inception and as its chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex's director of research and development, chief scientific officer, and as chief executive officer of Immunex’s R&D subsidiary. Dr. Gillis was interim chief executive officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.

Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.

Gary D. Glick, Ph.D.

Dr. Gary D. Glick founded Lycera in 2006, and was responsible for raising the seed round and Series A financing for the company. Since 1990, Dr. Glick has been a member of the chemistry faculty at the University of Michigan in Ann Arbor, where he presently holds the Werner E. Bachmann Chair in Chemistry. In addition, he is a professor in the department of biological chemistry at the University of Michigan Medical School and is a member of the training faculty for the interdepartmental immunology and medicinal chemistry doctoral programs. He is also the founder and director of the chemical biology doctoral program at Michigan. Dr. Glick’s research interests focus on drug discovery and development for autoimmune diseases and cancer, chemical-induced apoptosis, nucleic acid structure, folding and recognition, and molecular recognition of nucleic acids by proteins.

Dr. Glick has served and continues to serve on numerous boards and committees, including the Bioorganic & Natural Products Chemistry Study Section of the National Institutes of Health and the scientific advisory board of the National Arthritis Foundation, Michigan Chapter. He serves on several editorial boards, is editor-in-chief of Biopolymers, a leading journal publishing in the areas of biochemistry and biophysics, and is a counselor to the American Chemical Society Division of Biological Chemistry.

Dr. Glick’s scientific contributions have been recognized with a number of different awards including an Arthritis Investigator Award from the National Arthritis Foundation, a Junior Faculty Research Award from the American Cancer Society, a Young Investigator Award from the National Science Foundation, a Camille Dreyfus Teacher-Scholar Award, a Research Fellowship from the Alfred P. Sloan Foundation and two Research Excellence Awards from the University of Michigan. He is also a fellow of the American Association for the Advancement of Science.

Dr. Glick received a Ph.D. from Columbia University and completed a National Institutes of Health postdoctoral fellowship at Harvard University.

Robert Kamen, Ph.D.

Dr. Robert Kamen is a consultant to the biotech and pharmaceutical industry. Most recently, he was president of Abbott Bioresearch Center, Abbott Laboratories’ immunology drug discovery and biologics production unit in Worcester, Massachusetts, and a member of the Abbott Pharmaceuticals Executive Management Committee. During Dr. Kamen’s leadership at BASF/Abbott, the company established the technology platform for Humira™ (adalimumab), the first fully human antibody to achieve marketing approval in the U.S. (and Europe). Currently marketed for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and psoriasis, Humira was the most rapidly growing U.S. biological drug in 2007 and 2008. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, where he serves as chairman. In addition, Dr. Kamen is a member of several other biopharmaceutical company boards.

Dr. Kamen has an undergraduate degree in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.

Nina Kjellson

Nina Kjellson is a general partner at InterWest Partners, a leading diversified venture capital firm, where she focuses primarily on investments in biopharmaceuticals. Ms. Kjellson led InterWest’s investment in APT Pharmaceuticals and Nereus Pharmaceuticals where she is an observer on the board. Additionally, she supports InterWest’s investments in AkaRx, Devax, Kanisa and MacuSight. Ms. Kjellson’s past successfully exited investments include Aspreva Pharmaceuticals (acquired by Galenica) and NovaCardia (acquired by Merck). Prior to joining InterWest, Ms. Kjellson was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. She is also a board member of Alvine Pharmaceuticals, Eiger Biopharmaceuticals, Primera Diagnostics, Sequel and Trius Therapeutics.

Ms. Kjellson received a B.S. in human biology from Stanford University.

Jeffrey Leiden, M.D., Ph.D.

Dr. Jeffrey Leiden is a managing director at Clarus Ventures, a life sciences venture capital firm with more than $1.2 billion under management. He has more than 20 years of experience in the biomedical and pharmaceutical sectors. Dr. Leiden was president and COO of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Abbott board of directors and the TAP board of directors from 2000 to 2006.

From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor and chief of cardiology and director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and professor of medicine at Harvard Medical School. During his academic career, Dr. Leiden was involved in starting several biotechnology companies, including Vical and Cardiogene. He is an elected member of both the American Academy of Arts and Sciences, as well as the Institute of Medicine of the National Academy of Sciences.

Dr. Leiden is the chairman of the board of directors of both TyRx Pharma and Variation Biotechnologies Inc., and a member of the board of directors of Biolex Therapeutics. Dr. Leiden is also a non-executive director of Shire plc and a member of the Executive Committee of the Board of Trustees of the Ravinia Festival and a trustee of the University of Pennsylvania School of Medicine.

Dr. Leiden received both his M.D. and Ph.D. degrees from the University of Chicago and an honorary M.A. from Harvard University.

Tim Mayleben

Timothy M. Mayleben is an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. Prior to ElMa Advisors, he served as the president and chief operating officer and a director of NightHawk Radiology Holdings, Inc. Mr. Mayleben was formerly the chief operating officer of Esperion Therapeutics, which later became a division of Pfizer Global Research & Development. He joined Esperion in 1998 as chief financial officer, where he led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in December 2003. In addition, Mr. Mayleben serves on the advisory board for the Wolverine Venture Fund and is a director for several public and private life science companies.

Mr. Mayleben holds an M.B.A. with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. degree from the University of Michigan Ross Business School.

William J. Sibold

Bill Sibold is an accomplished leader with more than 20 years of pharmaceutical and biotechnology experience, with a focus on commercial operations, business development, general management and strategic planning. Prior to joining Lycera as CEO in 2010, Mr. Sibold was senior vice president, U.S. commercial at Biogen Idec, where he led the over $2.5 billion U.S. business that consisted of the oncology, rheumatology and neurology therapeutic areas. During his eight-year tenure at Biogen Idec, Mr. Sibold held multiple senior leadership roles at the company, which included growing the U.S. commercial business (Rituxan®, Avonex®, Tysabri®), leading the company’s new products group and managing the Australia and Asia Pacific regions. Mr. Sibold began his career in the biopharmaceutical industry with Eli Lilly Canada in sales and marketing, and then at Amgen in Epogen’s strategic marketing group.

In addition to his biotech and pharmaceutical experience, Mr. Sibold led the business development and sales departments of ICSL, one of the first site management organizations in the country that operated over 50 clinical trial sites with Phase 1 through 4 trial capabilities.

Mr. Sibold holds an M.B.A. from Harvard University and a B.A. in molecular biophysics and biochemistry from Yale University.